Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors

Bioorg Med Chem Lett. 2017 Jul 1;27(13):2943-2945. doi: 10.1016/j.bmcl.2017.05.004. Epub 2017 May 4.

Abstract

Among 18 human histone deacetylases (HDAC), HDAC11 is least studied. MS275, a benzamide HDAC inhibitor (HDACi), was stereotypically considered to selectively target Class I HDACs. We verified this slow-binding inhibitor also targeted HDAC11. In a traditional enzyme based assay, MS275 at low concentrations surprisingly behaved as an agonist. This was attributed to the poor stability of HDAC11 which lost 40% activity in 3h at 37°C. By adding 0.2μM SAHA, HDAC11 activity was stabilized during the 3-h assay period. Since 0.2μM SAHA inhibited 50% HDAC11 activity, the apparent IC50' of MS275 was adjusted to the true IC50=0.65μM. Finally, the new method demonstrated its superiority in one-dose-screening assays by decreasing false negative results. This work highlighted an optimized strategy to assay slow-binding inhibitors of unstable proteins with known fast-binding inhibitors. It should be especially useful in a hit-discovery stage to find moderate potent compounds.

Keywords: Chaperone molecule; HDAC11; Inhibitor screening; Slow-binding; Unstable protein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzamides / chemistry
  • Benzamides / pharmacology*
  • Dose-Response Relationship, Drug
  • Enzyme Stability / drug effects
  • Histone Deacetylase Inhibitors / chemistry
  • Histone Deacetylase Inhibitors / pharmacology*
  • Histone Deacetylases / chemistry*
  • Histone Deacetylases / metabolism*
  • Molecular Structure
  • Structure-Activity Relationship

Substances

  • Benzamides
  • Histone Deacetylase Inhibitors
  • benzamide
  • HDAC11 protein, human
  • Histone Deacetylases